On January 13, FOSUN PHARMA's subsidiary HENLIUS announced a licensing agreement with Abbott, granting it exclusive or semi-exclusive rights to develop and commercialize four self-developed biosimilars and one innovative drug in 69 Emerging Markets countries and regions. The agreement covers Asia, Latin America, the Caribbean, and the Middle East and North Africa. This licensing agreement further deepens the existing collaboration between both parties in the field of oncology biosimilars. According to the new agreement, the first batch of molecular candidates is expected to be launched by 2027, with the remaining products awaiting completion of clinical development and registration. Abbott will be responsible for the market registration of collaborative products in the cooperation area.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
复星医药子公司复宏汉霖与Abbott签署许可协议
FOSUN PHARMA's subsidiary HENLIUS has signed a licensing agreement with Abbott.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report